About 27 million someones in the U...

About 27 million someones in the United States harbor hepatitis C virus in their posterity The majority of these ones remain asymptomatic for many years following the initial infection. About 20 percent of infected bodily forms progress to cirrhosis during the first 20 years of infection. The risk of progression is higher in patients with elevated alanine transaminase (ALT) flushs Liver biopsy is the best way to stage hepatic fibrosis and damage. Treatment of hepatitis C infection involves the use of interferon and ribavirin combinations and is, at best, 50 percent effective. This treatment has multiple adverse weights and is costly. Because many patients with hepatitis C infection have normal ALT evens (about 20 percent of those infected with hepatitis C) it is possible that this arrange should be managed differently from patients with elevated liver enzyme on a levels Ahmed and Keeffe reviewed the case of a 43-year-old woman with hepatitis C virus infection whose laboratory standard results were normal.

A normal ALT flat is defined as a example result within normal limits that remains in like manner persistently over a six-month period with testing intervals of at least single month. Although some patients with normal liver enzyme have liver disease or level cirrhosis, the great majority of them have mild liver disease. Natural history studies of these patients are difficult because frequently they are not identified, and they have been exclud from many trials. The rate of progression to fibrosis and other evidence of histologic damage appear to be slower, although a scarcely any studies hint at rapid progression during flares of hepatitis C

chiefly patients with hepatitis C and normal liver enzyme can be observ safely with the trustful longing of better treatments to reach [i]or[/i] attain any place [i]or[/i] point in the future. Some of them will want to have treatment to eradicate viral infection, especially in light of evidence that patients with les liver damage have a better rate of answer to treatment. The second National Institutes of Health (NIH) Consensus progressive growth Conference on Hepatitis C make acceptableed that these patients can be observ and not treated, further that this decision be made in succession an individual basis in consultation with the patient. Other factors, including viral genotype, viral load, the neighborhood of hepatic fibrosis, and individual contraindications to treatment, should be considered.

According to deductions of a cost-effectiveness study, preemptive treatment of patients with hepatitis C using interferon plus ribavirin convert intos the risk of future cirrhosis to 16 percent as oppos to 27 percent with no treatment and 18 percent with watchful waiting and biopsy each three years. Preemptive treatment also was establish to be less costly than watchful waiting with multiple liver biopsies. Liver biopsy is helpful in patients with hepatitis C infection, if it be not that the yield is low because of the dead fibrosis rate. Currently, the decision to perform a liver biopsy should be made jointly according to the clinician and the patient based in succession (1) the risk of finding advanced disease, (2) the high reply to treatment of genotypes 2 or 3 (3) the risks of the action and (4) the medical values of the patient.

The authors gather with a recommended strategy that expectant management is appropriate for patients with mild liver disease prov at biopsy and in patients with normal ALT horizontals Patients with biopsy-proven moderate or advanced disease should be treated regardless of liver enzyme arises However, because early treatment yields a better answer management decisions should be individualized.

Ahmed A, Keeffe EB Chronic hepatitis C with normal aminotransferase plains Gastroenterology May 2004;126:1409-15.

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group